RBC Capital Reaffirms Their Buy Rating on Brookfield Infrastructure (BIP)
RBC Capital analyst Maurice Choy maintained a Buy rating on Brookfield Infrastructure (BIP – Research Report) on January 30 and set a price ...
RBC Capital Keeps Their Buy Rating on Mineral Resources Limited (MALRF)
RBC Capital analyst Kaan Peker maintained a Buy rating on Mineral Resources Limited (MALRF – Research Report) on January 30 and set a price ...
RBC Capital sets Greencore stock with Outperform, target at GBP2.40
RBC Capital initiated coverage on Greencore Plc (GNC:LN) (OTC: GNCGY), a prominent UK convenience food supplier with a market ...
RBC Capital lifts Celestica stock target to $140, keeps Outperform
RBC Capital Markets increased its price target on Celestica (NYSE:CLS) shares from $115.00 to $140.00 while maintaining an Outperform rating. Currently trading at $131.66, near its 52-week high, ...
Sarepta could be down on patient death in FDA database, says RBC Capital
RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that ...
Biggest of the Big Six: How RBC opened a $100-billion market-cap gap over its banking rivals
While Royal Bank focused on dealmaking in the U.S., its biggest domestic rival, TD, embraced retail banking — a 'cutthroat' ...
Alliance Pharma downgraded by RBC after weak H2, revenue miss
The downgrade comes after the company reported full-year revenue that fell 4% below market expectations, reflecting an underperformance in the second half of the year.
Energy & Utilities Roundup: Market Talk
Find insight on United Utilities, Viva Energy, Valero Energy and more in the latest Market Talks covering Energy and ...
RBC helps students expand their career horizons
Each year, RBC supports thousands of students from different educational backgrounds in exploring various career paths within ...
Investing3d
RBC Capital Markets upgrades EssilorLuxottica citing growth potential
Investing.com -- RBC Capital Markets has upgraded EssilorLuxottica (EPA:ESLX) to "outperform," citing strong fundamentals and growth opportunities in the ophthalmology sector. Shares of the ...